Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Improving outcomes in HCC with immunotherapy

Arndt Vogel • 11 Jun 2021
ASCO 2021
Gastrointestinal Cancer Liver Cancer Atezolizumab

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the extent of improved outcomes for patients with hepatocellular carcinoma (HCC) treated with immunotherapy, as well as ongoing Phase III studies further elucidating the optimal immunotherapeutic approaches in patients with HCC. This was discussed at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.

More from Arndt Vogel

2:17
The role of the PLATON Network in enhancing precision oncology
Arndt Vogel • 3 Jul 2023
3:14
RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC
Arndt Vogel • 3 Jul 2023
2:27
Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel • 3 Jul 2023
0:39
Analysis of the European/North American subgroup in the RATIONALE-301 trial
Arndt Vogel • 3 Jul 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals